Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers A > Headlines for Aurinia Pharmaceuticals Inc. > News item |
Aurinia announces plans to conduct $10 million at-the-market offering
Deal arranged with Cantor Fitzgerald; proceeds fund corporate purposes
By Devika Patel
Knoxville, Tenn., July 22 – Aurinia Pharmaceuticals Inc. negotiated a $10 million at-the-market equity offering with agent Cantor Fitzgerald & Co. on July 22, according to a prospectus supplement and 6-K filed Friday with the Securities and Exchange Commission.
Cantor will be paid a 3% commission.
Proceeds will be used for working capital and general corporate purposes, including the lupus nephritis clinical trial program for voclosporin.
The pharmaceutical company is based in Victoria, B.C.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.